Given that PRKCG and its phosphosites were downregulated in the BrM/BrM‐NAT group, the ultra‐high phosphorylation level of PRKCG at S330 in gliomas is particularly noteworthy (Figure 4D). Here, SMARCA2 is linked to central nervous system cancer.